CCL2 and hepatocellular carcinoma: Neutralizing antibody against CCL2/MCP-1 reduced the capability of inducing MSC chemotaxis toward CM derived from the human HCC tumors HuH7, HC-PT-5 or PT-19 by around a 20% while the anti-HGF antibody did not (Figure 2A).